The partnership will combine Evogene’s computational chemistry capabilities with the expertise of a team at QUT.
TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio.
Incredible advancements in lung cancer treatment are allowing doctors to target cancer with more precise drugs.
Shira Boehler shares her journey being diagnosed with Stage 1 lung cancer. A doctor explains the need for better lung cancer screening for asymptomatic, never smokers.
The new face of lung cancer is younger and harder to spot, like a woman who was getting a scan for something else after a ...
The US Food and Drug Administration (FDA) has granted marketing clearance to Eyonis LCS, an artificial intelligence-powered ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s ...
To address the awareness gap, the American Lung Association launched a website called “Saved by the Scan,” where anyone can take a quiz to see if they should get screened.
Following eyonis® LCS' FDA 510 (k) clearance announced on February 9, 2026, Median has activated a phased U.S. launch strategy designed for disciplined national expansion. The Company has conducted ...
Based on breakthrough findings from Dr. Adams' lab uncovering a novel druggable cellular detoxification pathway driving Cisplatin resistance in NSCLC, this collaboration aims to design novel ...
The best shot at curing cancer is catching it early, doctors say, but that doesn't always happen. Between 80% and 85% of pancreatic cancer cases aren't diagnosed until the aggressive and lethal ...
An NHS pilot has used a robotic catheter inserted into patient’s throat to reach spots as small as 6mm hidden deep in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results